What Elixirgen Therapeutics does

Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company founded in May 2017 and headquartered in Baltimore, Maryland, that develops gene- and cell-based therapies for rare genetic diseases and aging-associated conditions. The company operates as a subsidiary of Elixirgen, LLC and is co-led by CEO Aki Ko and CSO/co-founder Minoru Ko, MD, PhD, the latter being the original discoverer of the ZSCAN4 mechanism at the National Institute on Aging (NIH). Its pipeline rests on two proprietary technology platforms: ZSCAN4, a telomerase-independent telomere extension technology used in an autologous cell therapy for Telomere Biology Disorders (lead candidate EXG-34217, in Phase I/II under NCT04211714), and Bobcat® mRNA, a single-strand mRNA design capable of carrying payloads over 13 kilobases — exceeding the ~4.7 kilobase ceiling of conventional AAV vectors and enabling delivery of full-length dystrophin for Duchenne muscular dystrophy (lead candidate EXG-7001, preclinical). EXG-34217 has been granted FDA Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations, and early clinical data published in NEJM Evidence demonstrated the first-ever sustained telomere elongation in two treated patients.

Name

Elixirgen Therapeutics

Legal name

Elixirgen Therapeutics, Inc.

Website

https://ElixirgenTx.com

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

11–50 employees

Short description

Elixirgen Therapeutics is a clinical-stage biotechnology company developing gene and mRNA therapies for rare genetic diseases and aging-associated conditions, with lead programs in Telomere Biology Disorders and Duchenne Muscular Dystrophy.

Ownership category

akta.pro rank

Product category

Gene Therapy and mRNA Therapeutics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Gene Therapy for Rare/Monogenic Diseases (HLAAACAE)

akta.pro secondary industries

Cell Therapy Developers (Autologous) (HLAAABAA), mRNA Therapeutics (vaccines, protein replacement, immuno-oncology) (HLAAADAA)

Keywords

• Gene therapy therapeutics
• Rare disease biotechnology
• MRNA therapeutics platform
• Telomere biology disorders
• Duchenne muscular dystrophy therapy

Headquarters

HQ city

Baltimore

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Others

Revenue model

1. Therapeutic Development and Commercialization: Pre-revenue clinical stage biotechnology company developing gene therapies. Revenue will be generated through commercialization of proprietary therapeutics for rare diseases and aging-associated conditions upon successful clinical development and regulatory approval.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

Core offering

Elixirgen Therapeutics develops proprietary gene and mRNA-based therapeutic candidates for rare genetic diseases and aging-associated conditions. Its portfolio is anchored on two technology platforms: ZSCAN4, a telomerase-independent telomere extension technology used in its lead candidate EXG-34217 for Telomere Biology Disorders (Phase I/II), and Bobcat® mRNA, a single-strand mRNA delivery platform capable of carrying payloads over 13 kb used in EXG-7001 for Duchenne Muscular Dystrophy (preclinical). Revenue will be generated through out-licensing and strategic commercialization partnerships rather than direct sales.

Product overview

Elixirgen Therapeutics is a biotechnology company developing life-changing therapies for rare diseases and aging-associated diseases. Their product portfolio centers on two core technology platforms: ZSCAN4, a telomerase-independent telomere extension technology (lead candidate EXG-34217 in Phase I/II for Telomere Biology Disorders), and Bobcat® mRNA, a proprietary mRNA delivery platform capable of carrying large payloads over 13 kb (candidate EXG-7001 in preclinical stage for Duchenne muscular dystrophy).

Differentiator

Problem solved

Functional benefit

Products and services

• EXG-34217 Autologous cell therapy product candidate using ZSCAN4 telomere extension technology for the treatment of patients with Telomere Biology Disorders; granted FDA Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations; currently in Phase I/II clinical trial with early data published in NEJM Evidence demonstrating first-ever sustained telomere elongation in treated patients.
• EXG-7001 Bobcat® mRNA-based therapeutic candidate for Duchenne Muscular Dystrophy that encodes full-length dystrophin on a single mRNA strand; currently in preclinical phase with preclinical data demonstrating restoration of muscular function in DMD model mice and no safety findings associated with administration.

Quantifiable outcome

• First-ever successful sustained telomere elongation in two EXG-34217-treated patients with Telomere Biology Disorder with no treatment-related safety concerns over 24-month and 5-month periods
• +1 more outcomes

Segments3 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature2 records

Partnerships

Three partnerships are on record, tiered core.

• Nippon ShinyakucoreStrategic or Co-development Partner · 1 January 2025Elixirgen Therapeutics and Nippon Shinyaku entered into an option agreement for the development and commercialization of EXG-7001 for Duchenne Muscular Dystrophy. This strategic partnership enables Nippon Shinyaku to advance the Bobcat mRNA technology candidate in certain territories.
• National Institute on Aging (NIH)coreTechnology or IntegrationZSCAN4 technology was originally discovered at the National Institute on Aging, a division of the National Institutes of Health, by Chief Scientific Officer Minoru Ko and his team. This discovery forms the foundation of Elixirgen's lead therapeutic program.
• Cincinnati Children's Hospital Medical CentercoreStrategic or Co-development PartnerPhase I/II clinical trial (NCT04211714) for ZSCAN4 (EXG-34217) is being conducted at Cincinnati Children's Hospital Medical Center to study the autologous cell therapy in Telomere Biology Disorders patients.

Scale indicators2 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Sarepta Therapeutics: Commercial-stage developer of genetic medicines for Duchenne muscular dystrophy (Elevidys). Directly comparable as a DMD-focused therapeutics company pursuing gene-based approaches to large-gene monogenic disease.
• Rocket Pharmaceuticals: Clinical-stage gene therapy company developing AAV- and lentiviral-based therapies for rare monogenic diseases (e.g., Danon disease, Fanconi anemia, LAD-I). Closely comparable as a rare-disease gene therapy developer with a similar regulatory-designation strategy.
• Krystal Biotech: Commercial-stage gene therapy company (Vyjuvek for dystrophic epidermolysis bullosa) pursuing genetic medicines for rare diseases. Comparable as a rare-disease genetic medicines developer with FDA-designated assets and a similar platform-to-product pipeline model.
• bluebird bio: Gene therapy developer focused on severe genetic diseases (sickle cell disease, beta-thalassemia, cerebral adrenoleukodystrophy). Directly comparable as a rare-disease gene and cell therapy developer navigating similar regulatory and commercialization pathways.
• Regenxbio: Clinical-stage gene therapy company leveraging its proprietary AAV delivery platform across rare and ophthalmic diseases. Comparable as a platform-based gene therapy developer, although Bobcat mRNA differentiates Elixirgen by using a non-viral large-payload approach.
• Capricor Therapeutics: Clinical-stage cell therapy company developing allogeneic cardiosphere-derived cells for Duchenne muscular dystrophy and other rare diseases. Directly comparable as a cell-therapy developer targeting DMD with rare-disease regulatory designations.
• Solid Biosciences: Clinical-stage genetic medicines company focused exclusively on Duchenne muscular dystrophy, including AAV-mediated gene therapy and other modalities. Directly comparable as a DMD-focused therapeutic developer competing in the same indication.
• Tenaya Therapeutics: Clinical-stage genetic medicines company developing gene therapies, gene editing, and cellular reprogramming approaches for rare cardiac and neurological diseases. Comparable as a platform-based rare-disease genetic medicines developer.

Emerging players

• Generation Bio: Clinical-stage developer of non-viral genetic medicines using lipid nanoparticles and cell-targeted DNA delivery for rare diseases. Comparable as a non-viral gene-delivery platform company addressing payload-size limitations of AAV — analogous to Elixirgen's Bobcat approach.
• Verve Therapeutics: Clinical-stage developer of in vivo gene editing therapies for cardiovascular disease using base-editing and lipid nanoparticle delivery. Comparable as a developer of next-generation genetic medicines using novel delivery/editing mechanisms rather than conventional AAV.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/ElixirgenTx
• LinkedInlinkedin.com/company/elixirgen-therapeutics-inc

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Funding overview

Funding rounds5 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Elixirgen Therapeutics